Sino Medical Sciences Technology In Working Capital to Net Assets Ratio
Sino Medical Sciences Technology In working capital to net assets ratio. Sino Medical Sciences Technology In (688108) has a Working Capital to Net Assets ratio of 33.2% as of June 2026. Working capital of CN¥356.42 Million (current assets of CN¥570.53 Million minus current liabilities of CN¥214.11 Million) is measured against net assets of CN¥1.07 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 688108 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Sino Medical Sciences Technology In (2016–2025)
Working capital to net assets ratio of Sino Medical Sciences Technology In from 2016 to 2025. This chart shows how Sino Medical Sciences Technology In's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of June 2026, the ratio stands at 33.2%, reflecting working capital of CN¥356.42 Million against net assets of CN¥1.07 Billion CNY. See how many days can Sino Medical Sciences Technology In fund operations to measure how many days the company can operate on defensive assets alone.
Sino Medical Sciences Technology In Working Capital to Net Assets Ratio by Year (2016–2025)
Sino Medical Sciences Technology In working capital to net assets ratio by year from 2016 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Sino Medical Sciences Technology In from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Sino Medical Sciences Technology In (688108) total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 8.2% | CN¥186.64 Million | CN¥2.28 Billion | CN¥520.39 Million | CN¥333.75 Million | ▼ -15.3 pp |
| 2024 | 23.5% | CN¥211.37 Million | CN¥898.34 Million | CN¥403.39 Million | CN¥192.02 Million | ▲ +1.1 pp |
| 2023 | 22.4% | CN¥192.90 Million | CN¥861.65 Million | CN¥344.18 Million | CN¥151.27 Million | ▼ -2.7 pp |
| 2022 | 25.1% | CN¥222.72 Million | CN¥887.48 Million | CN¥354.90 Million | CN¥132.18 Million | ▼ -10.7 pp |
| 2021 | 35.8% | CN¥338.24 Million | CN¥945.16 Million | CN¥430.80 Million | CN¥92.56 Million | ▼ -22.8 pp |
| 2020 | 58.6% | CN¥631.26 Million | CN¥1.08 Billion | CN¥723.43 Million | CN¥92.18 Million | ▼ -7.7 pp |
| 2019 | 66.2% | CN¥727.70 Million | CN¥1.10 Billion | CN¥806.88 Million | CN¥79.18 Million | ▲ +1.7 pp |
| 2018 | 64.5% | CN¥452.29 Million | CN¥701.28 Million | CN¥535.37 Million | CN¥83.08 Million | ▼ -5.1 pp |
| 2017 | 69.6% | CN¥422.22 Million | CN¥606.70 Million | CN¥509.51 Million | CN¥87.29 Million | ▲ +26.7 pp |
| 2016 | 42.9% | CN¥86.90 Million | CN¥202.75 Million | CN¥150.72 Million | CN¥63.82 Million | — |